The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
Bayer (OTCPK:BAYRY) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its tyrosine kinase ...
A new oral HER2-directed breast cancer therapy from Bayer AG, and its companion diagnostic from Thermo Fisher Scientific Inc., have been approved by the U.S. FDA. Hyrnuo (sevabertinib), a reversible ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback